|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Thorgeirsson SS and Grisham JW: Molecular
pathogenesis of human hepatocellular carcinoma. Nat Genet.
31:339–346. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ohishi W, Kitamoto M, Aikata H, Kamada K,
Kawakami Y, Ishihara H, Kamiyasu M, Nakanishi T, Tazuma S and
Chayama K: Impact of aging on the development of hepatocellular
carcinoma in patients with hepatitis C virus infection in Japan.
Scand J Gastroenterol. 38:894–900. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ikai I, Arii S, Ichida T, Okita K, Omata
M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y and
Yamaoka Y: Report of the 16th follow-up survey of primary liver
cancer. Hepatol Res. 32:163–172. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thomas MB and Zhu AX: Hepatocellular
carcinoma: the need for progress. J Clin Oncol. 23:2892–2899. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shirabe K, Kanematsu T, Matsumata T,
Adachi E, Akazawa K and Sugimachi K: Factors linked to early
recurrence of small hepatocellular carcinoma after hepatectomy:
univariate and multivariate analyses. Hepatology. 14:802–805. 1991.
View Article : Google Scholar
|
|
7
|
Iizuka N, Oka M, Yamada-Okabe H, Nishida
M, Maeda Y, Mori N, Takao T, Tamesa T, Tangoku A, Tabuchi H, Hamada
K, Nakayama H, Ishitsuka H, Miyamoto T, Hirabayashi A, Uchimura S
and Hamamoto Y: Oligonucleotide microarray for prediction of early
intrahepatic recurrence of hepatocellular carcinoma after curative
resection. Lancet. 361:923–929. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shirabe K, Wakiyama S, Gion T, Motomura K,
Koyanagi T, Sakamoto S and Nagaie T: Clinicopathological risk
factors linked to recurrence pattern after curative hepatic
resection for hepatocellular carcinoma - results of 152 resected
cases. Hepatogastroenterology. 54:2084–2087. 2007.
|
|
9
|
Iizuka N, Oka M, Yamada-Okabe H, Mori N,
Tamesa T, Okada T, Takemoto N, Sakamoto K, Hamada K, Ishitsuka H,
Miyamoto T, Uchimura S and Hamamoto Y: Self-organizing-map-based
molecular signature representing the development of hepatocellular
carcinoma. FEBS Lett. 579:1089–1100. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Surowy CS, Hoganson G, Gosink J, Strunk K
and Spritz RA: The human RD protein is closely related to nuclear
RNA-binding proteins and has been highly conserved. Gene.
90:299–302. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cheng J, Macon KJ and Volanakis JE: cDNA
cloning and characterization of the protein encoded by RD, a gene
located in the class III region of the human major
histocompatibility complex. Biochem J. 294:589–593. 1993.
|
|
12
|
Yamaguchi Y, Takagi T, Wada T, Yano K,
Furuya A, Sugimoto S, Hasegawa J and Handa H: NELF, a multisubunit
complex containing RD, cooperates with DSIF to repress RNA
polymerase II elongation. Cell. 97:41–51. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamaguchi Y, Inukai N, Narita T, Wada T
and Handa H: Evidence that negative elongation factor represses
transcription elongation through binding to a DRB
sensitivity-inducing factor/RNA polymerase II complex and RNA. Mol
Cell Biol. 22:2918–2927. 2002. View Article : Google Scholar
|
|
14
|
Narita T, Yamaguchi Y, Yano K, Sugimoto S,
Chanarat S, Wada T, Kim DK, Hasegawa J, Omori M, Inukai N, Endoh M,
Yamada T and Handa H: Human transcription elongation factor NELF:
identification of novel subunits and reconstitution of the
functionally active complex. Mol Cell Biol. 23:1863–1873. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sakon M, Umeshita K, Nagano H, Eguchi H,
Kishimoto S, Miyamoto A, Ohshima S, Dono K, Nakamori S, Gotoh M and
Monden M: Clinical significance of hepatic resection in
hepatocellular carcinoma: analysis by diseasefree survival curves.
Arch Surg. 135:1456–1459. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tsunedomi R, Iizuka N, Tamesa T, Sakamoto
K, Hamaguchi T, Somura H, Yamada M and Oka M: Decreased ID2
promotes metastatic potentials of hepatocellular carcinoma by
altering secretion of vascular endothelial growth factor. Clin
Cancer Res. 14:1025–1031. 2008. View Article : Google Scholar
|
|
17
|
Waxman S and Wurmbach E: De-regulation of
common housekeeping genes in hepatocellular carcinoma. BMC
Genomics. 8:2432007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cheng AL, Huang WG, Chen ZC, Peng F, Zhang
PF, Li MY, Li F, Li JL, Li C, Yi H, Yi B and Xiao ZQ:
Identification of novel nasopharyngeal carcinoma biomarkers by
laser capture microdissection and proteomic analysis. Clin Cancer
Res. 14:435–445. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Poon RT, Ng IO, Fan ST, Lai EC, Lo CM, Liu
CL and Wong J: Clinicopathologic features of long-term survivors
and disease-free survivors after resection of hepatocellular
carcinoma: a study of a prospective cohort. J Clin Oncol.
19:3037–3044. 2001.PubMed/NCBI
|
|
20
|
Vauthey JN, Lauwers GY, Esnaola NF, Do KA,
Belghiti J, Mirza N, Curley SA, Ellis LM, Regimbeau JM, Rashid A,
Cleary KR and Nagorney DM: Simplified staging for hepatocellular
carcinoma. J Clin Oncol. 20:1527–1536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen X, Cheung ST, So S, Fan ST, Barry C,
Higgins J, Lai KM, Ji J, Dudoit S, Ng IO, van De Rijn M, Botstein D
and Brown PO: Gene expression patterns in human liver cancers. Mol
Biol Cell. 13:1929–1939. 2002. View Article : Google Scholar PubMed/NCBI
|
|
22
|
Okabe H, Satoh S, Kato T, Kitahara O,
Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y and Nakamura Y:
Genome-wide analysis of gene expression in human hepatocellular
carcinomas using cDNA microarray: identification of genes involved
in viral carcinogenesis and tumor progression. Cancer Res.
61:2129–2137. 2001.
|
|
23
|
Tsunedomi R, Iizuka N, Yamada-Okabe H,
Tamesa T, Okada T, Sakamoto K, Takashima M, Hamaguchi T, Miyamoto
T, Uchimura S, Hamamoto Y, Yamada M and Oka M: Identification of
ID2 associated with invasion of hepatitis C virus-related
hepatocellular carcinoma by gene expression profile. Int J Oncol.
29:1445–1451. 2006.PubMed/NCBI
|
|
24
|
Tanaka S, Mogushi K, Yasen M, Noguchi N,
Kudo A, Nakamura N, Ito K, Miki Y, Inazawa J, Tanaka H and Arii S:
Gene-expression phenotypes for vascular invasiveness of
hepatocellular carcinomas. Surgery. 147:405–414. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Iizuka N, Hamamoto Y, Tsunedomi R and Oka
M: Translational microarray systems for outcome prediction of
hepatocellular carcinoma. Cancer Sci. 99:659–665. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar
|
|
27
|
Matoba K, Iizuka N, Gondo T, Ishihara T,
Yamada-Okabe H, Tamesa T, Takemoto N, Hashimoto K, Sakamoto K,
Miyamoto T, Uchimura S, Hamamoto Y and Oka M: Tumor HLA-DR
expression linked to early intrahepatic recurrence of
hepatocellular carcinoma. Int J Cancer. 115:231–240. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Narita T, Yung TM, Yamamoto J, Tsuboi Y,
Tanabe H, Tanaka K, Yamaguchi Y and Handa H: NELF interacts with
CBC and participates in 3′ end processing of replication-dependent
histone mRNAs. Mol Cell. 26:349–365. 2007.PubMed/NCBI
|
|
29
|
Sun J, Watkins G, Blair AL, Moskaluk C,
Ghosh S, Jiang WG and Li R: Deregulation of cofactor of BRCA1
expression in breast cancer cells. J Cell Biochem. 103:1798–1807.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zou W, Yang Y, Wu Y, Sun L, Chi Y, Wu W,
Yun X, Xie J and Gu J: Negative role of trihydrophobin 1 in breast
cancer growth and migration. Cancer Sci. 101:2156–2162. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR,
Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici
M, Voliotis D and Bruix J: Sorafenib in advanced hepatocellular
carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J,
Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D and Guan Z:
Efficacy and safety of sorafenib in patients in the Asia-Pacific
region with advanced hepatocellular carcinoma: a phase III
randomised, double-blind, placebo-controlled trial. Lancet Oncol.
10:25–34. 2009. View Article : Google Scholar
|
